Article Text

Download PDFPDF
Safety and Efficacy of Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Radical Surgery Alone in Locally Advanced Cervical Cancer Patients
  1. Lin Gong, MD,
  2. Jia-Wen Zhang, MD,
  3. Ru-Tie Yin, MD,
  4. Ping Wang, MD,
  5. Hui Liu, MD,
  6. Ying Zheng, MD,
  7. Jiang-Yan Lou, MD and
  8. Zhi-Lan Peng, MD
  1. Department of Obstetrics and Gynecology, West China Second Hospital, West China Center of Medical Sciences, Sichuan University, Chengdu, China.
  1. Address correspondence and reprint requests to Zhi-Lan Peng, MD, Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, No. 20, Section 3, South People’s Rd, Chengdu, Sichuan 610041, China. E-mail: pengzhilan1{at}163.com.

Abstract

Objectives This study aimed to evaluate the safety and efficacy of neoadjuvant chemotherapy (NACT) followed by radical surgery (RS) among patients with locally advanced cervical cancer (LACC).

Methods Eight hundred patients with LACC received either NACT followed by RS (NACT–RS) or RS alone. The primary outcome measures assessed the efficacy and adverse effects of NACT. Secondary outcome measures compared the preoperative clinical stage to the postoperative pathologic stage in NACT–RS and RS patients, assessed intraoperative and postoperative complications, including the adverse effects of postoperative radiotherapy and radiochemotherapy, and estimated the 5-year progression-free survival and 5-year overall survival.

Results The clinical response to NACT was 89.54%. Patients in the NACT–RS group had lower preoperative hemoglobin levels (115.20 vs 122.04 g/L, P < 0.001), a longer operative time (mean, 233.66 vs 224.37 minutes, P = 0.008), more intraoperative bleeding (750.34 vs 684.41 mL, P = 0.011), a shorter duration of catheter use (mean, 29.84 vs 32.14 days, P = 0.036), and a lower incidence of postoperative complications (7.30% vs 13.62%, P = 0.002) and postoperative radiotherapeutic and radiochemotherapeutic adverse effects (3.16% vs 4.63%, P < 0.001) compared to patients in the RS group. The 5-year progression-free survival and 5-year overall survival were 80.30% and 81.10% in the NACT–RS group and 81.00% and 78.50% in the RS group (P > 0.05). Pathological poor differentiation, nonsquamous cell carcinoma, parametrial invasion, positive pelvic lymph node, and lymphovascular invasion (P < 0.05) were independent risk factors for recurrence.

Conclusions Neoadjuvant chemotherapy may reduce RS-associated complications and postoperative radiotherapeutic and radiochemotherapeutic adverse effects in Chinese patients with LACC.

  • Locally advanced cervical cancer
  • Neoadjuvant chemotherapy
  • Survival
  • Risk factors

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.